Published online Dec 26, 2017. doi: 10.4252/wjsc.v9.i12.235
Peer-review started: October 12, 2017
First decision: November 8, 2017
Revised: November 15, 2017
Accepted: December 3, 2017
Article in press: December 3, 2017
Published online: December 26, 2017
A 56-year-old male patient presented with joint stiffness and pain, skin lesions and fatigue.
Swelling, pain and reduced range of motion in the metacarpal and proximal phalangeal joints; joint symptoms progressed to include wrist and shoulder joints. Stiffness and pain were more pronounced on waking. Two years of arthritic symptoms preceded red, scaly skin lesions.
Rheumatoid arthritis, osteoarthritis, rheumatic fever, systemic lupus erythematosus, gout, secondary syphilis.
Values for C-reactive protein (CRP) and red blood cell sedimentation rate (ESR) became normal after cord blood stem cell (CBSC) treatment.
Anatomical pathology indicating psoriatic arthritis (PsA) resolved after treatment with CBSC.
Nonsteroidal anti-inflammatory drugs (NSAIDs), prednisone (steroid), methotrexate, TNF blockers (certolizumab and adalimumab), and umbilical cord blood stem cells.
Mesenchymal stem cells (from bone marrow or fat) have been used to treat rheumatoid arthritis.
Human umbilical cord blood was obtained from CorCell Cord Blood. Erythrocytes were removed using an ammonium chloride lysis buffer, used according to manufacturer’s directions (eBioScience). Flow analysis of similar preparations revealed about 3% of the population had the MSC marker, CD90+. Live, nucleated cells were concentrated by centrifugation, enumerated, and resuspended in cryopreservative (CryoGold Serum-Free Freezing Media, purchased from Stemgent, Inc.) The resulting samples were aliquoted into 1.8 mL cryogenic vials and gradually chilled to -160 ˚C. Immediately before use, cells were thawed and assessed for viability. Post thaw viability was 80%, as determined by an automated cell counter (Bio-Rad TC-20). Figure 3 shows one of the preparations administered to the patient.
This patient had persistent PsA symptoms, and did not find relief with standard therapies. Remission of symptoms correlated with injections of umbilical cord blood stem cells. Serological tests for inflammation (ESR and CRP) were normal for over a year after the initial CBSC injections.